NAYA Biosciences, Inc. (NAYA)
| Market Cap | 3.52M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 3.91M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 95,161 |
| Open | 0.810 |
| Previous Close | 0.813 |
| Day's Range | 0.810 - 0.909 |
| 52-Week Range | 0.631 - 3.500 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 19, 2024 |
About NAYA
NAYA Biosciences, Inc. focuses on developing clinical and commercial-stage assets for fertility, oncology, and autoimmune diseases. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma; and NY-338, a CD38-targeted FLEX-NK bispecific antibody for multiple myeloma and autoimmune diseases. The company also offers INVOcell, an IVC device that is an alternative to IVF that uses the female body for fertilization and incubation. The company was formerly known a... [Read more]
News
NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma
SARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in onco...
INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences
SARASOTA, Fla. and MIAMI, Oct. 21, 2024 (GLOBE NEWSWIRE) -- INVO Biosciences (Nasdaq: INVO), a company focused on expanding its portfolio of clinical and commercial-stage assets in fertility, oncology...
INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)
Combined company to expand portfolio of clinical & commercial-stage assets in fertility, oncology, and autoimmune diseases Combined company to expand portfolio of clinical & commercial-stage assets in...
INVO Reports Record First Quarter 2024 Financial Results
SARASOTA, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatme...
INVO Reports Fourth Quarter and Full Year 2023 Financial Results
SARASOTA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treat...
NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal
Abstract from 2023 American Society of Hematology (ASH) Meeting Data demonstrates differentiated profile from DARZALEX® (daratumumab) with best-in-class potential, supports initiation of clinical tria...
NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies
NAYA Biosciences and ONK Therapeutics to assess proof-of-concept and establish activity and feasibility of the combination of NAYA's FLEX-NK™ bispecific antibodies and ONK's optimally engineered natur...
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
SARASOTA, Fla. , Nov. 28, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services company focused on expanding access to advanced fertility treatment...
INVO Reports Record Third Quarter 2023 Financial Results
Company Expects to Host Conference Call Shortly After November 20, 2023 Following the Progress of Certain Closing Conditions Pertaining to the Announced Merger Agreement with NAYA Biosciences SARASOTA...
NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger
SARASOTA, Fla. and AVENTURA, Fla.
INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase Warrants
SARASOTA, Fla. , Nov. 9, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services company focused on expanding access to advanced fertility treatment ...
INVO BIOSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of INVO Bioscience, Inc. - INVO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of INVO Bioscienc...
INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company
Post-merger, the combined company, operating under the name "NAYA Biosciences", will be dedicated to increasing patient access to life-transforming treatments in oncology, fertility, and regenerative ...
INVO to Participate in the Lytham Partners Fall 2023 Investor Conference
SARASOTA, Fla. , Oct. 11, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment...
INVO BIOSCIENCE ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF SHAREHOLDERS
SARASOTA, Fla. , Sept. 29, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company") today announced that its special meeting of shareholders on September 29, 2023 (the "Spec...
INVO Reminds Shareholders to Cast Their Vote for Upcoming Special Meeting of Shareholders to be held on Friday, September 29, 2023 at 12:00 p.m. ET
SARASOTA, Fla. , Sept. 28, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatmen...
INVO Bioscience, Inc. (INVO) Q2 2023 Earnings Call Transcript
INVO Bioscience, Inc. (NASDAQ:INVO) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Robert Blum - Investor Relations Steve Shum - Chief Executive Officer Mike Campbel...
INVO Reports Second Quarter 2023 Financial Results
Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla. , Aug. 14, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility compan...
INVO Closes Acquisition of Wisconsin Fertility Institute
Transformational and accretive acquisition adds significant scale to INVO's current operations Contributes over $5 million in incremental annual revenue as well as positive net income and cash flows F...
INVO to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , Aug. 9, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a healthcare serv...
INVO Bioscience Announces Closing of $4.5 Million Public Offering
SARASOTA, Fla. , Aug. 8, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment ...
INVO Bioscience Announces Pricing of $4.5 Million Public Offering
SARASOTA, Fla. , Aug. 4, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment w...
INVO Sets Revised Closing Date of Wisconsin Fertility Institute Acquisition and Announces Key Operational Trends to Drive Shareholder Value
Company sets closing date deadline of acquisition to August 10, 2023 -- Acquisition is expected to significantly enhance total annual revenue and contribute positive net income to the company's operat...
INVO Announces a 1:20 Reverse Stock Split Effective Pre-Market Opening on July 28, 2023
SARASOTA, Fla. , July 27, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment wo...
INVO Receives 510(k) FDA Clearance for Expanded Use of the INVOcell Device
INVOcell now cleared for 5-day incubation period Supporting data reflects improved patient outcomes, similar to IVF SARASOTA, Fla. , June 27, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ...